Next generation product may increase gastrointestinal luminal concentration while limiting system exposure
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health...
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.
Shares of Bausch Health, Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO. The industry declined 0.6% during this...
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin...
LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources.
A large red number on the bottom line attracted the wrong kind of investor attention for the company.
Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical company’s unusual options activity suggests it might have more gains ahead.
/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch Health Companies Inc. (NYSE: BHC) between...